BCIQ Profiles

Target Profile Report

Minerva’s schizophrenia miss casts doubt on approach to treating negative symptoms

Minerva’s Phase III miss in schizophrenia sent its shares down 72% on Friday, putting into doubt the future of the leading therapeutic candidate in development to treat the negative symptoms of schizophrenia -- an indication that causes much of the disability associated with the neuropsychiatric disorder.

Despite the loss of investor confidence, Minerva Neurosciences Inc.

Read the full 545 word article

How to gain access

Continue reading with a
two-week free trial.